Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04805515
Other study ID # 00001374
Secondary ID R01DA051001
Status Completed
Phase N/A
First received
Last updated
Start date February 12, 2021
Est. completion date May 31, 2021

Study information

Verified date November 2022
Source University of Vermont
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a 2-arm, randomized controlled, population based trial to test the impact of multiple exposures to brief nicotine corrective messages among adult tobacco cigarette smokers and non-smokers followed in waves over 12 weeks. The primary outcome, assessed at wave 1 (baseline), wave 2 (weeks 5-6), and wave 4 (weeks 11-13) is nicotine beliefs. Secondary outcomes assessed at the same time points include intention to use nicotine/tobacco products and nicotine/tobacco use.


Description:

This is a 2-arm, randomized controlled, population based trial to test the impact of multiple exposures to brief nicotine corrective messages among adult tobacco cigarette smokers and non-smokers followed for 12 weeks. The primary outcome, assessed at wave 1 (baseline), wave 2 (weeks 5-6), and wave 4 (weeks 11-13) is nicotine beliefs. Secondary outcomes assessed at the same time points include intention to use nicotine/tobacco products and nicotine/tobacco use. All participants will be recruited from a US national consumer research panel. Eligible participants will be U.S. adults ages 18+ who are enrolled members of the partnering consumer research panel. The sample will include non-smokers and smokers, oversampling current smokers (defined as smoking 100+ lifetime cigarettes and now smoking all or some days) to ensure the proportion of smokers in the sample reflects the ~15 % population smoking prevalence among adults. Panel members will be contacted by email with a brief study description and link to an eligibility screener and online informed consent form. Eligible and interested participants will complete the baseline (Wave 1) survey measures of nicotine beliefs and intentions/use of nicotine and tobacco products, after which they will be randomly assigned in equal numbers to the nicotine corrective message (NCM) intervention condition or the delayed message control condition. After completing the baseline survey, participants in the NCM condition will receive their first exposure to the corrective messages. In the Wave 2 survey, all participants will complete measures of nicotine beliefs and intentions/use of nicotine and tobacco products. Participants in the NCM condition will then receive their second exposure to study messages. Only participants in the NCM condition will receive the Wave 3 survey, which involves the third exposure to study messages. The Wave 4 survey will include the fourth exposure to study messages for those in the NCM condition and the final assessment of nicotine beliefs and intentions/use of nicotine and tobacco products for all participants. Upon completion of the final assessment, participants in the control condition will be exposed to the nicotine corrective messages and all participants will be directed to resources on quitting smoking.


Recruitment information / eligibility

Status Completed
Enrollment 794
Est. completion date May 31, 2021
Est. primary completion date May 31, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - US resident age 18+ - Member of the partnering consumer research panel conducting the survey - Non-smokers and tobacco cigarette smokers Exclusion Criteria: - Age less than 18 - Not a member of the partnering consumer research panel conducting the study

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Nicotine Corrective Messages
Messages communicating misperceptions of nicotine's role in health harms as well as misperceptions about reduced nicotine content cigarettes and e-cigarettes.

Locations

Country Name City State
United States University of Vermont Burlington Vermont

Sponsors (2)

Lead Sponsor Collaborator
University of Vermont National Institute on Drug Abuse (NIDA)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Attitudes About Nicotine Three items on nicotine-related attitudes using semantic differentials across five-point Likert scales. 'Using Nicotine is:' Safe (1) - Dangerous (5); Positive (1) - Negative (5); Good (1) - Bad (5). Wave 4 (weeks 11-13)
Other Nicotine Related Norms Two items: "How would you describe most people's opinion of using nicotine?" and "Thinking about the people who are important to you, how would you describe their opinion on using nicotine?" with five-point Likert scale responses ranging from "very negative" (1) to "very positive" (5). Higher scores indicate positive norms of using nicotine. Wave 4 (weeks 11-13)
Other Behavioral Control One item assessing confidence to resist smoking cigarettes when others are smoking (1=not at all confident to 4=very confident). Wave 4 (weeks 11-13)
Primary Nicotine Beliefs 3 items assessing nicotine false beliefs (range 3-11), 6 items assessing nicotine replacement therapy (NRT) false beliefs (range 4-20), 4 items assessing e-cigarette false beliefs (range 2-14), 11 items assessing reduced nicotine content (RNC) cigarette false beliefs (range 14-45), and two items assessing beliefs about additive-free and organic tobacco products. Higher scale scores indicate a higher number of false beliefs. Wave 4 (weeks 11-13)
Secondary Intention to Use Nicotine/Tobacco Products Four items assessing intention to use tobacco cigarettes, e-cigarettes, NRT, and RNC cigarettes during the next 12 months. Adapted from PhenX Toolkit- Susceptibility to Tobacco Products, response options Definitely Yes; Probably Yes; Probably Not; Definitely Not. Outcomes reported for participants reporting Definitely Yes or Probably Yes to each item. Wave 4 (weeks 11-13)
Secondary Tobacco Use Number of days used tobacco in the past 30 days. Days used summed across eight different nicotine/tobacco products (e.g., tobacco cigarettes, e-cigarettes, cigars, NRT, RNC cigarettes). Wave 4 (weeks 11-13)
See also
  Status Clinical Trial Phase
Completed NCT05477342 - Reducing Nicotine Addiction in Adolescent Smokers N/A
Completed NCT03011710 - Epidemiology and Acute Oral Effects Electronic Cigarette N/A
Recruiting NCT03194919 - Negotiating a Quit Date or Not in Online Interventions N/A
Recruiting NCT03191825 - Online Lapse Management Intervention N/A
Completed NCT03719391 - United States Pre-Market Tobacco Application Pharmacokinetics N/A
Completed NCT05538702 - Acute Oral Effects of Heated Tobacco Products N/A
Completed NCT02723162 - Translational Neuropsychopharmacology Research of Nicotine Addiction Phase 2
Completed NCT03194958 - Helping Poor Smokers Quit N/A
Completed NCT03593239 - Comparing the Pharmacokinetics of Nicotine Salt Based ENDS in Healthy Smokers N/A
Completed NCT04830384 - Evaluation of LLLT/Music for Smoking Cessation N/A
Completed NCT02367391 - Penn State TXT2Quit Study N/A
Recruiting NCT05665465 - Neurobehavioral Mechanisms Linking Childhood Adversity to Increased Risk for Smoking Early Phase 1
Completed NCT03700112 - Clinical Study Comparing 7 ENDS Products and 1 Combustible Cigarette Using 2 Delivery Methods. N/A
Terminated NCT02986711 - Penn State TXT2STAYQUIT Study- a Texting Study to Help Hospitalized Smokers Stay Quit N/A
Recruiting NCT05224154 - Re-Connect Application for Smoking Cessation N/A
Completed NCT03492463 - The Role of Nicotine Dose and Route of Delivery in Affecting Adoption of E-cigarettes and Reducing Exposure to Toxic Combustion Products Phase 2
Withdrawn NCT03473483 - Cigarette Harm Reduction With Electronic Cigarette Use N/A
Completed NCT04379388 - Improving Smoking Cessation in Socioeconomically-Disadvantaged Young Adults N/A
Active, not recruiting NCT04163081 - The INITIATE Study: Initiating Nicotine Dependence Treatment for Smokers Admitted to Emergency Departments N/A